Disclosure of Share Capital and Voting Rights
Outstanding as of July 31, 2018

(Pursuant to Article L.233-8 II of the French Commercial Code
and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (August 6, 2018 – 6.00 p.m.) – As of July 31, 2018, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

<table>
<thead>
<tr>
<th>July 31, 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shares outstanding</td>
</tr>
<tr>
<td>Exercisable voting rights</td>
</tr>
<tr>
<td>Total voting rights, based on all outstanding shares, including shares stripped of their voting rights*</td>
</tr>
</tbody>
</table>

(*) Shares held by the Company.

About Essilor
Essilor International (Compagnie Générale d’Optique) (“Essilor”) is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, Bolon™ and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.

Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit www.essilor.com.

The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.

Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16